Literature DB >> 23462483

Diabetes is associated with postural instability and gait difficulty in Parkinson disease.

Vikas Kotagal1, Roger L Albin, Martijn L T M Müller, Robert A Koeppe, Kirk A Frey, Nicolaas I Bohnen.   

Abstract

BACKGROUND: Comorbid diabetes may be associated with more severe motor impairment in Parkinson disease. In normal elderly individuals, diabetes is associated with parkinsonian features, including gait difficulty and rigidity, though not tremor. Whether diabetes contributes to increased motor dysfunction in Parkinson disease by exacerbating nigrostriatal dopaminergic denervation or through intensification of extranigral pathology is unknown.
METHODS: We performed a case-control study (n = 39) involving 13 Parkinson disease subjects (age 66.4yrs ± 5.5; duration of disease 6.9yrs ± 4.4) with diabetes and 26 age, gender, and duration-of-disease-matched Parkinson disease controls without diabetes. All subjects underwent [(11)C]dihydrotetrabenazine vesicular monoamine transporter type-2 positron emission tomography imaging to assess striatal dihydrotetrabenazine distribution volume ratio and Unified Parkinson disease rating scale motor examination to determine rigidity, bradykinesia, tremor, and postural instability and gait difficulty subscores. Magnetic resonance imaging scans were analyzed to assess leukoaraiosis burden.
RESULTS: After controlling for nigrostriatal dopaminergic denervation, Parkinson disease subjects with diabetes displayed greater postural instability and gait difficulty subscores (t = 3.81, p = 0.0005). There were no differences in bradykinesia, rigidity, or tremor subscores between cases and controls. The association between diabetes and postural instability and gait difficulty persisted after controlling for comorbid hypertension and body mass index. Leukoaraiosis, distal vibratory sense, and levodopa dose equivalents did not differ significantly between cases and controls.
CONCLUSIONS: Diabetes may contribute to postural instability and gait difficulty in Parkinson disease through mechanisms other than nigrostriatal dopaminergic denervation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23462483      PMCID: PMC3607954          DOI: 10.1016/j.parkreldis.2013.01.016

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  31 in total

1.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Authors:  Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

2.  Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.

Authors:  R A Koeppe; K A Frey; D E Kuhl; M R Kilbourn
Journal:  J Cereb Blood Flow Metab       Date:  1999-12       Impact factor: 6.200

Review 3.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

4.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

5.  Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study.

Authors:  Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2003-02-19       Impact factor: 17.088

Review 6.  Central nervous system inflammation in disease related conditions: mechanistic prospects.

Authors:  Anthony Fung; Marcela Vizcaychipi; Dafydd Lloyd; Yanjie Wan; Daqing Ma
Journal:  Brain Res       Date:  2012-02-02       Impact factor: 3.252

7.  Neuropathy in Parkinson disease: prevalence and determinants.

Authors:  Yusuf A Rajabally; Jean Martey
Journal:  Neurology       Date:  2011-11-02       Impact factor: 9.910

8.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

9.  Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections.

Authors:  N I Bohnen; C W Bogan; M L T M Müller
Journal:  Eur Neurol J       Date:  2009-09

Review 10.  The relationship between diabetes mellitus and Parkinson's disease.

Authors:  R Sandyk
Journal:  Int J Neurosci       Date:  1993 Mar-Apr       Impact factor: 2.292

View more
  34 in total

1.  Clinical markers for identifying cholinergic deficits in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen; Vikas Kotagal; Peter J H Scott; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease.

Authors:  M Petrou; C Davatzikos; M Hsieh; B R Foerster; R L Albin; V Kotagal; M L Müller; R A Koeppe; W H Herman; K A Frey; N I Bohnen
Journal:  Acad Radiol       Date:  2016-02-10       Impact factor: 3.173

Review 3.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

4.  Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease.

Authors:  Nicolaas I Bohnen; Vikas Kotagal; Martijn L T M Müller; Robert A Koeppe; Peter J H Scott; Roger L Albin; Kirk A Frey; Myria Petrou
Journal:  Parkinsonism Relat Disord       Date:  2014-10-15       Impact factor: 4.891

Review 5.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

6.  Gastric emptying, postprandial blood pressure, glycaemia and splanchnic flow in Parkinson's disease.

Authors:  Laurence G Trahair; Thomas E Kimber; Katerina Flabouris; Michael Horowitz; Karen L Jones
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

Review 7.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

8.  Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients.

Authors:  Hai Jun Li; Ying Yu; Ying Chen; Hai Yan Liang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  Cardiovascular Risk Factor Burden in Veterans and Non-Veterans with Parkinson Disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

10.  The role of prefrontal cortex during postural control in Parkinsonian syndromes a functional near-infrared spectroscopy study.

Authors:  Jeannette R Mahoney; Roee Holtzer; Meltem Izzetoglu; Vance Zemon; Joe Verghese; Gilles Allali
Journal:  Brain Res       Date:  2015-11-06       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.